cinnarizine 🐢 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihistaminics/cerebral (or peripheral) vasodilators 654 298-57-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cinnarizin
  • cinnarizine
  • cinaperazine
  • cinarizine
  • cinnipirine
A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.
  • Molecular weight: 368.52
  • Formula: C26H28N2
  • CLOGP: 6.05
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -5.33
  • ROTB: 6

Drug dosage:

DoseUnitRoute
90 mg O
90 mg O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vestibular migraine 70.47 38.31 10 742 207 50604165
Therapeutic response changed 57.02 38.31 10 742 823 50603549
Endometrial cancer 44.64 38.31 10 742 2873 50601499

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vestibular migraine 41.59 30.99 6 950 140 64497636
Medication overuse headache 38.54 30.99 7 949 703 64497073
Portal tract inflammation 34.28 30.99 5 951 126 64497650
Pneumoconiosis 31.09 30.99 5 951 243 64497533

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07CA02 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
ANTIVERTIGO PREPARATIONS
Antivertigo preparations
ATC N07CA52 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
ANTIVERTIGO PREPARATIONS
Antivertigo preparations
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:37955 H1 receptor antagonists
CHEBI has role CHEBI:37956 antihistamines
CHEBI has role CHEBI:38215 calcium channel blockers
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:50857 anti-allergic drugs
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:176497 geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Motion sickness indication 37031009 DOID:2951
Vertigo indication 399153001
Nausea indication 422587007




🐢 Veterinary Drug Use

None

🐢 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.42 Basic
pKa2 3.42 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mu-type opioid receptor GPCR Ki 6.04 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 6.59 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 6.78 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.77 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.24 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.55 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 6.21 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.99 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.33 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.99 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 7.07 DRUG MATRIX
Histamine H1 receptor GPCR Ki 8.06 DRUG MATRIX
Histamine H4 receptor GPCR Ki 6.85 PDSP
Muscarinic acetylcholine receptor M1 GPCR Ki 6.22 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.79 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.29 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 6.26 DRUG MATRIX
Alpha-2C adrenergic receptor GPCR Ki 7.02 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.89 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 6.24 DRUG MATRIX
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 6.36 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 6.30 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor IC50 6.79 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 5.72 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.97 CHEMBL

External reference:

IDSource
N0000167127 NUI
D01295 KEGG_DRUG
2549 RXNORM
C0008803 UMLSCUI
CHEBI:31403 CHEBI
N90 PDB_CHEM_ID
CHEMBL43064 ChEMBL_ID
DB00568 DRUGBANK_ID
D002936 MESH_DESCRIPTOR_UI
1547484 PUBCHEM_CID
9072 IUPHAR_LIGAND_ID
1021 INN_ID
3DI2E1X18L UNII
003951 NDDF
349958007 SNOMEDCT_US
395955001 SNOMEDCT_US

Pharmaceutical products:

None